Remynd NV reported encouraging Phase IIa clinical trial results for its novel Alzheimer's drug candidate REM-127. The orally administered small molecule restores calcium homeostasis in neurons, successfully reducing pathological tau proteins—a hallmark of Alzheimer’s—in affected patients. Additionally, the drug increased dopamine levels and yielded positive cognitive outcomes. This double-blind, placebo-controlled trial represents a promising advance targeting tau-induced neuronal dysfunction, opening new therapeutic avenues for neurodegenerative disease treatment.